cyrilzakka/clinical-trials huggingface dataset:
The Effect of Anti-Gravity Treadmill Training in Patients With Meniscus Tears

The aim of this study is to evaluate the effect of anti-gravity treadmill training on symptoms and functions in patients with meniscus tears.

Meniscus tears are one of the most common sports-related injuries. Acute trauma-related tears are more common in active young individuals and athletes. Symptoms such as pain, effusion, tenderness at the joint line, locking, and knee dysfunction are observed after injury. It is aimed to provide painless movement, normal knee kinematics, and retaining of muscle strength in rehabilitation process. Anti-gravity treadmills use an inflatable space around the lower extremities and significantly reduce body weight during walking and running. Anti-gravity treadmill training protects the joint and surrounding soft tissues against the negative effects of loading during the post-injury recovery process, and allows the tissues to heal safely. The aim of this study is to evaluate the effect of anti-gravity treadmill training on symptoms and functions in patients with meniscus tears.

Patients will be randomly divided into three groups: Anti-Gravity Treadmill Group, Conventional Treadmill Group, and Control Group. All patients will be included physiotherapy and rehabilitation program for 6 weeks, 2 days a week. While subjects in the Anti-Gravity Treadmill Group will participate to training anti-gravity treadmill walking, subjects in the Conventional Treadmill Group will participate walking program on a standard treadmill. Symptoms and functions will be assessed baseline and after 6-week program.

Eligibility Criteria:
Inclusion Criteria:

* Age between 18-40 years old
* Clinical history and symptoms consistent with MRI-confirmed meniscus tear

Exclusion Criteria:

* History of previous knee surgery
* Other knee ligament pathologies
* Neurological disorders
Mangement of Pulmonary Emboli

To assess to which extent we are adherent to ESC guidelines 2019 in management of patients presented with acute pulmonary embolism

Pulmonary embolism (PE) is the third most frequent cardiovascular disease and is associated with a high mortality burden PE is defined as the obstruction of a pulmonary artery, mostly resulting from the dislodgement of thrombotic material from the lower limbs. It has a wide variety of presentations, ranging from an asymptomatic incidental finding to circulatory collapse and sudden death Pulmonary embolism response teams (PERTs) have emerged as a multidisciplinary team for managing acute pulmonary embolism, with a rapid activation process for multimodality assessment, risk stratification and best management especially for complex challenge cases. PERTs help in improving time to PE diagnosis; shorter time to initiation of anticoagulation reducing hospital length of stay, increasing use of advanced therapies as catheter directed therapies without an increase in bleeding complications with decreasing mortality

Eligibility Criteria:
Inclusion Criteria:

* No includion criteria

Exclusion Criteria:

* No exclusion criteria
Yoga for Chronic Headache in Adolescents

A randomized controlled trial to investigate the efficacy of yoga on tension type headache and / or migraine in adolescents between 12 and 16 years, consisting of a four group design which includes an 12 week yoga course and a three-month follow-up period. Both adolescent and one parent will be randomized either to yoga or no treatment. Primary outcome will be pain frequency in adolescents considering pain catastrophizing of parents.


Eligibility Criteria:
Inclusion Criteria:

Adolescent:

* tension type headache and/or migraine minimum at 4 days per month
* willingness to participate at least 10 out of 12 yoga sessions
* physical and cognitive ability to participate in light physical, breathing and relaxation exercises
* good german language

Parents:

* willingness to participate at least 10 out of 12 yoga sessions
* physical and cognitive ability to participate in light physical, breathing and relaxation exercises
* good german language

Exclusion Criteria:

* pregnancy or lactation
* attending a yoga class within the last 3 months prior to the study
Gastric Emptying of Maltodextrin Solution in Elderly and in Adults

Gastric volume will be measured before, 5, 30, 60, 90 and 120 min after drinking 450ml of maltodextrin in young adults and elderly.

Gastric volume will be estimated before, 5, 30, 60, 90 and 120 min after drinking 450ml of maltodextrin in young adults and elderly using antral ultrasound.

Eligibility Criteria:
Inclusion Criteria:

* ASA physical status I or II;
* No known risk factor for slow or fast gastric emptying.

Exclusion Criteria:

* Vomiting the study solution before completion.
* Wrong timing of assessment.
* Protocol violation.
The Natural History of Small Airways Physiology in Diseased and Healthy States

Spirometry is a useful clinical tool for the assessment and monitoring of lung disease, however, it does not provide information on peripheral airways resistance. On the contrary, impulse oscillometry (IOS) may provide information not only on airway resistance (Rrs) but also on the elastic properties of the lung (Xrs). In addition, multiple breath nitrogen washout (MBNW) utilizes the exhalation of nitrogen gas from the airways to determine changes in lung ventilation and derive small airways indices (that tells us about small airways calibre). This method, like IOS, allows a precise assessment of small airways function.

Even though patients with asthma may show some reduction of the caliber of the small airways these changes are more a feature of patients with COPD. The study team hypothesize that IOS and MBNW measurements may detect these differences and provide different resistance profiles for asthma and COPD. Furthermore, the study team would like to investigate the relationship between airway inflammation and small airway disease by measuring exhaled nitric oxide (NO) at multiple exhalation flow rates. This technique allows the partitioning of NO produced in the central airways from that generated more peripherally in the lung, providing valuable information on the activity of inflammation in different parts of the respiratory system. The study team hope that the combined use of IOS, MBNW and NO will identify a possible correlation between inflammation and small airway dysfunction.

Background

The main objective of this study is to measure the damage of the small airways in lung disease exploring the "silent zone" with methods that have not been used before together in the same patients. Furthermore, because this is a 4 year longitudinal study, the study team will investigate the time related changes of small airway function in lung disease and normal healthy subjects.

The study will also investigate the relationship between small airway resistance and inflammation.

Eligibility Criteria:
Inclusion Criteria:

* male or female, aged between 18-85 years;
* volunteers who are able to give written informed consent Patients meeting the diagnostic criteria for asthma, COPD, ILD, CF, chronic cough.

Exclusion Criteria:

* upper respiratory tract infection within the previous 28 days
* any history or evidence of renal, cardiovascular, gastrointestinal or hepatic disease
* any history and evidence of neuropsychiatric disease
* treatment with antibiotics within 4 weeks prior to the study
* alcohol, drug abuse or any other condition associated with poor compliance
* breast feeding
* pregnancy
* are unable to provide written informed consent
Transbronchial Cryobiopsy in Lung Transplant Patients

Cryobiopsy has displaced the transbronchial biopsy (BTB) with forceps because it allows to obtain samples of more representative pulmonary parenchyma with more alveoli, less artifacts and a greater diagnostic yield. However, some authors report an increase in adverse effects such as hemorrhage and pneumothorax. The latest ISHLT (International Society for Heart and Lung Transplantation) consensus of 2007 recommends that with BTB with forceps a minimum of five tissue samples should be obtained that should contain more than 100 wells or the presence of two bronchioles to Which may be necessary between 3 and 17 samples. The optimal number of transbronchial cryobiopsies is unknown in order to obtain maximum performance with the lowest possible morbidity.

It is proposed to analyze the morphological and histopathological characteristics of each cryobiopsies individually and in order of extraction, to determine the sensitivity in the diagnosis of acute rejection as a function of the number of samples. Lung transplant patients, not admitted to critical units, with BTB indication will be included. A maximum of 6 samples will be obtained by flexible bronchoscope and under general anesthesia.

These data will allow to know the minimum number of specimens that guarantee a histological and / or bacteriological diagnosis of certainty with maximum effectiveness.

Transbronchial biopsies (BPTB) will be performed using a flexible bronchoscope and the biopsy will be performed with cryoprobe (Erbokryo®). The patient undergoing the procedure will be intubated, sedated and relaxed under continuous monitoring (pulse oximetry, blood pressure, heart and respiratory rate), oxygen therapy with high flows and surveillance by anesthesiologist. The site where the biopsies will be performed will be determined based on an imaging study (chest x-ray and / or CT scan). The procedure will be performed according to the conventional technique, keeping the patient in apnea during the time that the cryobiopsies are taken to reduce the risk of pneumothorax. At most 6 samples will be obtained, and each one will be placed in an individual container listed in order of extraction. Bronchoalveolar lavage (3 aliquots of 30 mL sterile saline solution) will be performed in the same hemithorax. The samples obtained will be evaluated morphologically and sent to a microbiological and histopathological study, which will include a cell count. The data obtained will be coded.

Eligibility Criteria:
Inclusion Criteria:

* Pulmonary transplant patients with suspected rejection or infection requiring transbronchial biopsy

Exclusion Criteria:

* Respiratory failure refractory to oxygen therapy.
* Acute or subacute ischemic heart disease (last 4-6 weeks).
* Severe arrhythmias.
* Coagulation disorders: platelets \<60,000-50,000 or Prothrombin time \<60%.
* Lack of consent informed.
Comparing Salmeterol/Fluticasone Easyhaler and Seretide Diskus (SAIMI)

The purpose of this study is to compare absorption of salmeterol and fluticasone from Salmeterol/fluticasone Easyhaler test products to the commercially available product Seretide Diskus


Eligibility Criteria:
Main inclusion Criteria:

1. Written informed consent (IC) obtained.
2. Males and females, 18-60 (inclusive) years of age.
3. Normal weight defined as body mass index (BMI) 19-30 kg/m2 (BMI = weight/height2).
4. Weight at least 50 kg.

Main exclusion Criteria:

1. Evidence of a clinically significant cardiovascular, renal, hepatic, haematological, GI, pulmonary, metabolic, endocrine, neurological or psychiatric disease.
2. Any condition requiring regular concomitant treatment.
3. Any clinically significant abnormal laboratory value or physical finding that in the opinion of the investigator may interfere with the interpretation of study results or constitute a health risk for the subject if he/she takes part in the study.
4. Known hypersensitivity to the active substance(s) or the lactose.
5. Pregnant or lactating females and females of childbearing potential not using proper contraception.
6. Blood donation or loss of significant amount of blood within 90 days prior to first study treatment administration.
7. Administration of another investigational medicinal product within 90 days prior to first study treatment administration.
Improving Self-Efficacy, Resolving Inflammaging Allo HSCT Survivors in Personal Training

This protocol is a pilot study of a personalized and supervised 10-week strength training program to improve self-efficacy and resolve biomarkers of inflammaging in a cohort of allogeneic hematopoietic transplant (HCT) long-term survivors versus healthy controls.


Eligibility Criteria:
Healthy Volunteers: must be the friends or relatives of the cancer patients enrolled in this study.

Inclusion Criteria:

* HCT recipients

  * Age ≥ 18 years
  * Greater than 6 months after completing systemic multiagent chemotherapy (greater than 12 months for HCT participants) at the time of enrollment. Maintenance chemotherapy is allowed
  * In remission from cancer Off immunosuppression, or on a stable immunosuppression regimen with prednisone doses ≤ 20 mg daily, with no changes planned to the immunosuppression regimen during the study period
  * Karnofsky performance status ≥ 50% (Appendix III)
  * Platelet count ≥ 50,000 without transfusions
  * Absolute neutrophil count ≥ 1
  * Willing to complete weekly strength training sessions for 10 consecutive weeks and complete all pre- and post-testing (self-efficacy survey and research blood draw)
  * Currently reside within the Minneapolis-St. Paul metro area
  * Has an adult (age ≥ 18) friend or relative who is willing to serve as an exercise partner and healthy control for the study
  * If known diabetic: Stable doses of medications to treat diabetes within 4 weeks prior to enrollment
  * Willing and able to sign voluntary written consent
* Healthy Controls

  * Age ≥ 18 years
  * Karnofsky performance status ≥ 50%
  * Willing to complete weekly strength training sessions for 10 consecutive weeks and complete all pre- and post-testing (self-efficacy survey and research blood draw)
  * Currently reside within the Minneapolis-St. Paul metro area
  * If known diabetic: Stable doses of medications to treat diabetes within 4 weeks prior to enrollment
  * Willing and able to sign voluntary written consent

Exclusion Criteria for both Cancer Survivors and Controls

* Presence of an external central venous catheter (Hickman, PICC, etc); Port-a-cath devices that are completely internal are allowed
* Use of ≥ 20+ mg prednisone daily
* Current or planned use of investigational drugs during the study period
* Myocardial infarction or stroke within 6 months
* Heart failure graded Class IV on New York Heart Association (NYHA) scale (https://manual.jointcommission.org/releases/TJC2018A/DataElem0439.html)
* Any medical condition that the consenting medical provider deems would make the participant unsafe to perform a 10-week strength training program
* Are currently pregnant
Pelvic Floor Muscle Training on the Quality of Life in Women With Urinary Incontinence

Aim: To assess the influence of pelvic floor muscles group training in the quality of life and functionality of these muscles in women with UI.

Study design: This is a randomized controlled trial.

Search location: Urogynecology Ambulatory Care of Porto Alegre Clinical Hospital (HCPA)

Patients or participants: Women will be included in aged 35-70 years who have had sexual intercourse in the last 12 months and who are able to understand the instruments, besides signing an informed consent form. Women will be excluded with latex allergy, who have made pelvic radiotherapy, or be undergoing chemotherapy, puerperal a year, or who use antidepressants and / or anxiolytics.

Intervention and measures: The evaluation consists of a medical history form, which will include personal data; the assessment of the MAP function is performed by the pressure biofeedback; for assessment of quality of life will use the questionnaire ICQI-SF and sexual function the PISQ-12 before and after Pelvic Floor Muscle Training.

Expected results: To estimate effectiveness of Pelvic Floor Muscle Training in the quality of life and functionality of these muscles in women with urinary incontinence.

Eligibility Criteria:
Inclusion Criteria:

* Female;
* Have urinary incontinence;
* Age between 35 and 70 years;
* Have sexual intercourse in the last 6 months;
* Participants should understand the instruments used in the research;
* Accept to participate in the study and sign the Term of Free and Informed Consent.

Exclusion Criteria:

* Latex allergy;
* Have performed or are undergoing pelvic radiotherapy;
* Be performing chemotherapy treatment;
* Women who delivered during the last 12 months;
* Have participated in individual or group MAP training in the last 6 months;
* Have contraction of the pelvic floor muscles grade zero (0).
3D Airway Model for Pediatric Patients

To determine the correct size of endotracheal tubes (ETT) for endotracheal intubation of pediatric patients is no menial task. Although new methods have been investigated to determine ETT size, and the three-dimensional (3D) printing technology has been successful in the field of surgery, there are not many studies in the field of anesthesia. The purpose of this study is to evaluate the accuracy of a 3D airway model for prediction of the correct ETT size, and compare the results with a conventional age-based formula in pediatric patients.

To determine the correct size of endotracheal tubes (ETT) for endotracheal intubation of pediatric patients is no menial task. Although new methods have been investigated to determine ETT size, and the three-dimensional (3D) printing technology has been successful in the field of surgery, there are not many studies in the field of anesthesia. The purpose of this study is to evaluate the accuracy of a 3D airway model for prediction of the correct ETT size, and compare the results with a conventional age-based formula in pediatric patients. : Thirty five pediatric patients under 6 years of age who were scheduled for congenital heart surgery. In the pre-anaesthetic period, the patient's computed tomography (CT) images were converted to STL files using the 3D conversion program. An FDM type 3D printer was used to print 3D airway models from the sub-glottis to the upper carina. ETT size was selected by inserting various sized cuffed-ETTs to a printed 3D airway model.

Eligibility Criteria:
Inclusion Criteria:

* children under 6 years of age (range 4 days to 61 months) scheduled for surgery for congenital heart disease with chest computed tomography (CT) images including upper airways

Exclusion Criteria:

* pediatric patients with intubation or tracheostomy before general anesthesia due to underlying disease
* small sized airway with inner diameter \<3.0 mm because of pre-term or low birth weight
* unstable vital signs during induction
* history of difficult intubation
* emergency surgery where printing a 3D airway model in advance was not possible
Treatment Patterns And Outcomes In Patients Treated With Benefix Or Refacto/Refacto AF - A Swedish Cohort Study

The overall aim of the study is to describe demographic and clinical characteristics, treatment patterns and outcomes, in the populations of hemophilia patients treated with BeneFIX and ReFacto/ReFacto AF in Sweden

The overall aim of the study is to describe demographic and clinical characteristics, treatment patterns and outcomes, as well as the related direct treatment costs in the populations of hemophilia patients treated with BeneFIX and ReFacto/ReFacto AF, and in subgroups (e.g. level of severity) at the MHC in Sweden.

The study population will consist of all patients diagnosed with haemophilia (D66.9 (haemophilia A) D67.9 (haemophilia B) in International Statistical Classification of Diseases and Related Health Problems (ICD-10) that have been registered in the MHR since 1977 and that have had at least one registered prescription of BeneFIX or ReFacto/ReFacto AF in the MHR since market authorization of the respective product (Benefix August 27 1997, ReFacto April 13 1999, ReFacto AF July 1 2009). Diseased individuals are included. Information on drugs picked up at the pharmacy is available in the Prescribed Drug Register from 2005.

Eligibility Criteria:
Inclusion Criteria:

* The study population will consist of all patients diagnosed with hemophilia (D66.9 (hemophilia A) D67.9 (hemophilia B) in International Statistical Classification of Diseases and Related Health Problems (ICD-10) that have been registered in the Malmö Hemophilia Register since 1977 and that have had at least one registered prescription of BeneFIX or ReFacto/ReFacto AF in the MHR since market authorization of the respective product

Exclusion Criteria:

* No exclusion criteria in this study
Association Between Mitochondrial DNA Content and Risk of Coronary Heart Disease

Compelling epidemiological evidence indicates that alterations of mitochondrial DNA, including mutations and abnormal content of mitochondrial DNA (mtDNA), are associated with the initiation and development of cardiovascular disease. This study was undertaken to investigate whether mtDNA copy number in peripheral blood cells could be used as a risk predictor for coronary heart disease.


Eligibility Criteria:
Inclusion Criteria:

1. History of documented myocardial infarction;
2. Prior coronary revascularization intervention (coronary artery bypass graft surgery or percutaneous coronary intervention);
3. The presence of ≥ 50% stenosis in one or more coronary arteries identified during cardiac catheterization;

Exclusion Criteria:

1. History of malignancy or end-stage renal disease;
2. Blood transfusion within one month or prior bone marrow transplantation
3. Patients who reluctant to sign informed consent